Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Change in Cash (2016 - 2025)

Cytosorbents' Change in Cash history spans 15 years, with the latest figure at -$1.3 million for Q4 2025.

  • Quarterly results put Change in Cash at -$1.3 million for Q4 2025, up 46.46% from a year ago — trailing twelve months through Dec 2025 was -$2.0 million (up 65.94% YoY), and the annual figure for FY2025 was -$2.0 million, up 65.94%.
  • Change in Cash for Q4 2025 was -$1.3 million at Cytosorbents, up from -$2.7 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $5.6 million in Q4 2023 to a low of -$12.9 million in Q2 2022.
  • The 5-year median for Change in Cash is -$2.9 million (2021), against an average of -$3.2 million.
  • The sharpest move saw Change in Cash crashed 349.73% in 2022, then soared 1465.95% in 2023.
  • Year by year, Change in Cash stood at -$7.2 million in 2021, then soared by 94.35% to -$407672.0 in 2022, then soared by 1465.95% to $5.6 million in 2023, then plummeted by 143.17% to -$2.4 million in 2024, then skyrocketed by 46.46% to -$1.3 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at -$1.3 million, -$2.7 million, and -$1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.